NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

You’re misquoting the NYAS presentation.

The May 10, 2022 NYAS deck does not show an HR of 1.01 for near-total resection patients. That is so typically you, providing a link to a source but not quoting it. What it shows are subgroup slides (significant residual disease, minimal residual disease, age, MGMT, etc.) with directional forest plots. The data were presented visually not with subgroup hazard ratios spelled out. The take-home message from that meeting was:
* Residual disease patients showed “unanticipated benefit.
* Older patients also showed unexpected benefit.
* Minimal residual disease appeared neutral.
* And across all comers, DCVax-L extended OS and demonstrated long-tail survival versus controls.

So claiming “HR = 1.01” as if it were formally disclosed at NYAS is not accurate. That number doesn’t appear in the deck. Unless someone has another source, it looks like you’re repeating a second-hand number rather than citing what was actually presented.

As per usual, EX's source: 👍️ (and that's not a thumbs up for OK...)

Ps:

Agreed. I am not attempting to "prove" that -L was not effective. Just noting concerns in the data that make it difficult to assert it has been proven it was effective.

You kinda did. If it works, the data will reflect this, and given the lethal orphan designation, it will be approved. You just admitted to that.